5-硝基喹喔啉-6-胺 | 62088-30-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 5-硝基喹喔啉-6-胺
• 英文名称: 5-nitro-6-quinoxalylamine
• 英文别名: 5-nitro-quinoxalin-6-ylamine；5-Nitro-chinoxalin-6-ylamin；6-Amino-5-nitro-chinoxalin；6-Quinoxalinamine, 5-nitro-；5-nitroquinoxalin-6-amine
• CAS: 62088-30-6
• 化学式: C₈H₆N₄O₂
• 分子量: 190.161
• InChiKey: ACLARZMXAHTZQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  97.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-硝基喹喔啉-6-胺 以 乙醇 为溶剂， 生成 6-amino-5-hydroxyquinoxaline
  参考文献：
  名称：

  Phototransformations of 6-X-5-Nitroquinoxalines

  摘要：

  Photophysical properties and photochemical activity of 6-X-5-nitroquinoxalines with electrondonor substituents (X = H, CH3, Cl, OC2H5, NH2) ortho to the nitro group were studied. The quantum yield of the formation of 5-hydroxyquinoxaline from the corresponding nitro derivative depends on the nature of the substituent and irradiation conditions. Phototransformations can go through nitro-nitrite rearrangement with the participation of two alternative T(pipi*) levels, depending on the size and electronic effects of the substituent. The latter factor is largely determined by the population on excitation of different charge-transfer states involving the nitro group.

  DOI：

  10.1023/b:rugc.0000030402.66220.55
• 作为产物：
  描述：

  2,4-二硝基苯胺 在 硫酸 、 氢气 、 硝酸 、 镍 作用下， 以 水 、 异丙醇 为溶剂， 反应 26.0h， 生成 5-硝基喹喔啉-6-胺
  参考文献：
  名称：

  Phototransformations of 6-X-5-Nitroquinoxalines

  摘要：

  Photophysical properties and photochemical activity of 6-X-5-nitroquinoxalines with electrondonor substituents (X = H, CH3, Cl, OC2H5, NH2) ortho to the nitro group were studied. The quantum yield of the formation of 5-hydroxyquinoxaline from the corresponding nitro derivative depends on the nature of the substituent and irradiation conditions. Phototransformations can go through nitro-nitrite rearrangement with the participation of two alternative T(pipi*) levels, depending on the size and electronic effects of the substituent. The latter factor is largely determined by the population on excitation of different charge-transfer states involving the nitro group.

  DOI：

  10.1023/b:rugc.0000030402.66220.55

文献信息

• 一种制备6-氨基-5-硝基喹喔啉的方法
  申请人：安徽皓元药业有限公司

  公开号：CN113880778B

  公开（公告）日：2023-07-25

  本发明提供一种制备6‑氨基‑5‑硝基喹喔啉的方法，反应如下：其中，R1选自2‑硝基苯磺酰基，3‑硝基苯磺酰基，4‑硝基苯磺酰基或2，4‑二硝基苯磺酰基；本发明使用中间体化合物新颖，制备6‑氨基‑5‑硝基喹喔啉的方法简便，反应条件较温和，收率高，成本更低，且得到产品纯度高，有利于工业化生产，为后续制备高质量药品提供了保证。
• [EN] N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS DE N2-PHÉNYLPYRIMIDINE-2,4-DIAMINE ET PROCÉDÉS DE PRÉPARATION ET PROCÉDÉS D'UTILISATION CORRESPONDANTS
  申请人：BRIDGE BIOTHERAPEUTICS INC

  公开号：WO2022208454A1

  公开（公告）日：2022-10-06

  The present disclosure relates to novel N2-phenylpyrimidine-2,4-diamine compounds, method for preparing the same, and pharmaceutical composition or health functional food for the prevention or treatment of cancer, containing the same as an active ingredient. The novel N2- phenylpyrimidine-2,4-diamine compounds show potent inhibitory efficacies on EGFR mutations and thus, can be effectively used for the treatment of cancer with EGFR mutations.

  本公开涉及新型N2-苯基嘧啶-2,4-二胺化合物、其制备方法以及包含其作为活性成分的预防或治疗癌症的药物组合物或保健功能食品。新型N2-苯基嘧啶-2,4-二胺化合物对EGFR突变具有强大的抑制效果，因此可以有效用于治疗EGFR突变的癌症。
• Substituted 1,10-Phenanthrolines. XI. Aza Derivatives¹
  作者：Francis H. Case、James A. Brennan

  DOI：10.1021/ja01532a046

  日期：1959.12
• DÉRIVÉS AMINO-QUINOXALINES POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：Centre National de la Recherche Scientifique (C.N.R.S.)

  公开号：EP2691377B1

  公开（公告）日：2018-03-07
• AMINOQUINOXALINE DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Ferrie Laurent

  公开号：US20140113903A1

  公开（公告）日：2014-04-24

  The present invention relates to compounds of formula (I) below: for which: —X represents a hydrogen atom, a halogen atom, a group NO 2 or NH 2 , —R 0 represents H or —CH 2 —C≡CH, and —R 1 and R 2 each represent, independently of one another, a hydrogen atom; a saturated or unsaturated, linear or branched hydrocarbon-based chain comprising from 1 to 10 carbon atoms; or an optionally substituted aryl group, and also the pharmaceutically acceptable salts thereof, the stereoisomers thereof or mixtures of stereoisomers thereof in any proportion, in particular for use thereof as a medicament, in particular in the treatment or prevention of neurodegenerative diseases, and also the processes for the preparation thereof and the pharmaceutical compositions comprising same.